Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage
Clinics and Practice · 07.08.2026 · 16 (8) · 146
DOI: 10.3390/clinpract16080146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinics and Practice, online erschienen am 07.08.2026. Verfasst von Nicoletta Bernardini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, La Sapienza University of Rome, Polo Pontino, 0410…. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Guselkumab, a monoclonal antibody selectively targeting the p19 subunit of interleukin-23, is typically administered with an induction phase at weeks 0 and 4 followed by maintenance dosing every 8 weeks for the treatment of psoriatic arthritis (PsA). In Europe, a four-week regimen (Q4W) has recently been approved for patients at high risk of joint damage progression; however, real-world evidence on this intensified schedule remains limited. This study aimed to evaluate the effectiveness and safety of guselkumab Q4W in routine clinical practice.
Methods
This retrospective observational study included 18 PsA patients at high risk of structural damage treated with guselkumab Q4W at two psoriasis referral centers in the Lazio region of Italy. Baseline and 24-week clinical data were collected from medical records. Outcome measures included Disease Activity Index for Psoriatic Arthritis (DAPSA), Minimal Disease Activity (MDA), pain Visual Analog Scale (VAS), Dermatology Life Quality Index (DLQI), and Psoriasis Area and Severity Index (PASI).
Results
After 24 weeks, mean DAPSA decreased from 34.3 ± 7.6 to 3.7 ± 3.0; 55.6% of patients achieved DAPSA remission and 77.8% achieved MDA. Significant improvements were observed in pain VAS, DLQI, and PASI scores. All patients achieved PASI 75, while 83.3% achieved PASI 90 and PASI 100. Treatment was generally well tolerated, with no adverse events or new safety signals documented during follow-up.
Conclusions
In our study, guselkumab Q4W showed marked multidomain effectiveness and a favorable safety profile, supporting its use in PsA patients at high risk of joint damage progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, La Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy.
- Unit of Dermatology, Department of Medical and Cardiovascular Sciences, La Sapienza University of Rome, 00161 Rome, Italy.
- Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Italy.
- Gastroenterology Unit, Department of Medical-Surgical Sciences and Biotechnologies, La Sapienza University of Rome, Polo Pontino, 04100 Latina, Italy.
ORCID-Profile: Nicoletta Bernardini, Giorgio Marotta, Nevena Skroza, Maria Consiglia Bragazzi, Umberto Gallo, Antonio Giovanni Richetta, Annunziata Dattola
Zitieren
APA
Bernardini, N., Marotta, G., Skroza, N., Graceffa, D., Bragazzi, M. C., Finistauri Guacci, L., Tolino, E., Sasso, F. P., Gallo, U., Richetta, A. G., & Dattola, A. (2026). Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage. Clinics and Practice, 16(8), 146. https://doi.org/10.3390/clinpract16080146
Vancouver
Bernardini N, Marotta G, Skroza N, Graceffa D, Bragazzi MC, Finistauri Guacci L, et al. Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage. Clinics and Practice. 2026;16(8):146. doi:10.3390/clinpract16080146
BibTeX
@article{Bernardini2026,
author = {Bernardini, Nicoletta and Marotta, Giorgio and Skroza, Nevena and Graceffa, Dario and Bragazzi, Maria Consiglia and Finistauri Guacci, Lucia and Tolino, Ersilia and Sasso, Francesca Paola and Gallo, Umberto and Richetta, Antonio Giovanni and Dattola, Annunziata},
title = {Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage},
journal = {Clinics and Practice},
year = {2026},
volume = {16},
number = {8},
pages = {146},
doi = {10.3390/clinpract16080146}
}
EUVIMED